Fig. 4

Targeting NCAPG2 inhibits the growth of PCa in vivo. a Representative images of subcutaneous xenograft derived from the sh-NCAPG2 and sh-NC DU145 cells. b, c Tumor volume and body weight in nude mice of sh-NCAPG2 and sh-NC group were measured every 5 days. d, e The size and weights of subcutaneous tumors in the sh-NCAPG2 group were significantly lower than the sh-NC group. f Representative bioluminescence images of orthotopic xenograft. g Tumor growth curves of orthotopic tumor in vivo were determined based on BLI radiance measured every 5 days. h, i The orthotopic tumors in sh-NCAPG2 group were smaller and lighter, compared with the sh-NC group. j Growth curve of body weight between the sh-NCAPG2 and sh-NC groups. PCa prostate cancer, BLI bioluminescence. P values were calculated by the Student’s t-test. * means P < 0.05, ** means P < 0.01, *** means P < 0.001, ns means P > 0.05, and P < 0.05 is defined as statistically significant